References


Address for correspondence: Vanessa R. Barrs, Department of Veterinary Clinical Sciences, Jockey Club College of Veterinary Medicine, City University of Hong Kong, Kowloon Tong, Hong Kong, China; email: vanessa.barrs@cityu.edu.hk

Lack of Susceptibility to SARS-CoV-2 and MERS-CoV in Poultry

David L. Suarez, Mary J. Pantin-Jackwood, David E. Swayne, Scott A. Lee, Suzanne M. DeBlois, Erica Spackman

Author affiliation: US Department of Agriculture, Athens, Georgia, USA

DOI: https://doi.org/10.3201/eid2612.202989

We challenged chickens, turkeys, ducks, quail, and geese with severe acute respiratory syndrome coronavirus 2 or Middle East respiratory syndrome coronavirus. We observed no disease and detected no virus replication and no serum antibodies. We concluded that poultry are unlikely to serve a role in maintenance of either virus.

Coronaviruses of animals periodically transmit to humans (1), as recently occurred with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 was recognized in December 2019 in cases of atypical pneumonia in hospitalized patients in Wuhan, China. The virus is a novel betacoronavirus, related to the now-eradicated severe acute respiratory syndrome coronavirus (SARS-CoV) from 2003, with which SARS-CoV-2 has 82% identity across the genome (2). SARS-CoV-2 is highly transmissible among humans and particularly virulent for elderly persons and those with certain underlying health conditions. Multiple studies have examined the susceptibility of domestic animals to SARS-CoV-2 to establish the risk for zoonotic transmission; 2 studies have shown chickens and Pekin ducks were not susceptible to infection (3,4).

Middle East respiratory syndrome coronavirus (MERS-CoV), another coronavirus of high concern associated with zoonotic infection, was first detected in patients with severe acute lower respiratory tract disease in Saudi Arabia in 2012. MERS-CoV causes lower respiratory disease, similar to the SARS-CoVs (5). Unlike SARS-CoV-2, MERS-CoV transmits poorly to humans and does not exhibit sustained human-to-human transmission; however, it has a high case fatality rate of ~30%. Although the MERS-CoV case count is low, human cases continue to be reported, therefore there is a possibility for the virus to adapt to humans.

Based on sequence similarity, the closest relatives of SARS-CoV-2 and MERS-CoV are believed to be bat betacoronaviruses (6); the sequence difference
between human and bat isolates suggests the existence of an intermediary host. For MERS-CoV, dromedary camels appear to be the primary natural reservoir of infection to humans, but other domestic animals seem to be susceptible to infection (7,8). Hemida et al. looked for MERS-CoV antibodies in chickens; all samples were negative (9).

Because poultry are so widespread and have close and extended contact with humans and other mammals in many production systems, including live animal markets, we conducted susceptibility studies with SARS-CoV-2 and MERS-CoV in 5 common poultry species. Embryonating chicken eggs (ECE) have been used for virus isolation culture, including use in vaccine production, for diverse avian and mammalian viruses; therefore, we tested ECE for their ability to support the replication of both viruses.

We examined 5 poultry species: chickens (Gallus gallus domesticus), turkeys (Meleagris gallopavo), Pekin ducks (Anas platyrhinchos domesticus), Japanese quail (Coturnix japonica), and white Chinese geese (Anser cygnoides). The US National Poultry Research Center Institutional Animal Care and Use Committee reviewed and approved all procedures involving animals; the Institutional Biosafety Committee approved the use of the viruses.

To evaluate their susceptibility to these viruses, 10 birds of each species were challenged with a virus isolate obtained from the Biodefense and Emerging Infections Research Resources Repository (BEI Resources; National Institute of Allergy and Infectious Diseases, National Institutes of Health). We used either the USA-WA1/2020 isolate of SARS-CoV-2 (BEI NR-58221) or the Florida/USA-2_SaudiArabia_2014 isolate of MERS-CoV (BEI NR-50415) (Appendix, https://wwwnc.cdc.gov/EID/article/26/12/20-2989-App1.pdf).

We collected oropharyngeal and cloacal swabs from all birds at 2, 4, and 7 days postchallenge (dpc) and tested them for virus by real-time reverse transcription PCR. At 14 dpc we collected serum specimens from the birds and tested for antibody to the challenge virus by microneutralization. No clinical signs were observed at any time in any species, and virus was not detected in any swab material (Table). Antibodies were not detected in serum from any birds at 14 dpc. These results suggest that neither virus replicates in any of the avian species evaluated or that they replicated at a level that was too low to be detected.

We tested ECE for their ability to support SARS-CoV-2 or MERS-CoV replication after inoculation with any of the 3 most common routes: yolk sac, chorioallantoic sac, or chorioallantoic membrane (Appendix). We collected yolk, allantoic fluid (albumin), and embryo tissues from inoculated eggs; we tested for viral replication by attempting virus isolation in Vero cells from the egg material after each of 2 ECE passages. We did not recover either virus in Vero cells from the inoculated ECEs, nor did we observe lesions in any of the embryos inoculated with SARS-CoV-2 or MERS-CoV. The ECE results with SARS-CoV-2 are consistent with the results reported by Barr et al. (10).

Identifying potential reservoir hosts of the novel coronaviruses is critical to controlling exposure and subsequent infection, as well as to preserving a safe and consistent food supply. None of the avian species nor the ECE appeared to support replication of either virus. Our findings demonstrate that poultry are unlikely to serve a role in the maintenance or transmission of either SARS-CoV-2 or MERS-CoV, and furthermore that ECE are not a viable laboratory host system.

| Table. Poultry testing positive for SARS-CoV-2 or MERS-CoV, United States* |
|------------------|------------------|------------------|
| Species          | SARS-CoV-2        | MERS-CoV         |
|                  | No. positive at 2 dpc | No. positive at 4 dpc | No. positive at 7 dpc | Antibody | No. positive at 2 dpc | No. positive at 4 dpc | No. positive at 7 dpc | Antibody |
| Chickens (Gallus gallus domesticus) | OP 0 | CL 0 | OP 0 | CL 0 | OP 0 | CL 0 | Antibody 0 | OP 0 | CL 0 | Antibody 0 |
| Turkeys (Meleagris gallopavo) | OP 0 | CL 0 | OP 0 | CL 0 | OP 0 | CL 0 | Antibody 0 | OP 0 | CL 0 | Antibody 0 |
| Japanese quail (Coturnix japonica) | OP 0 | CL 0 | OP 0 | CL 0 | OP 0 | CL 0 | Antibody 0 | OP 0 | CL 0 | Antibody 0 |
| Pekin ducks (Anas platyrhinchos) | OP 0 | CL 0 | OP 0 | CL 0 | OP 0 | CL 0 | Antibody 0 | OP 0 | CL 0 | Antibody 0 |
| Chinese domestic geese (Anser cygnoides) | OP 0 | CL 0 | OP 0 | CL 0 | OP 0 | CL 0 | Antibody 0 | OP 0 | CL 0 | Antibody 0 |

*Real-time reverse transcription PCR was used to test the oropharyngeal and cloacal swabs collected from 10 individuals of each poultry species inoculated with SARS-CoV-2 or MERS-CoV. We tested serum samples for antibody 14 dpc by virus neutralization assay. Three birds of each species served and mock-infected controls; CL, cloacal swab; dpc, days postchallenge; MERS-CoV, Middle East respiratory syndrome coronavirus; OP, oropharyngeal swab; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Acknowledgments
We thank Jesse Gallagher, Melinda Vonkungthong, Anne Hurley-Bacon, Jasmina Luczo, James Doster, and Charles Foley for technical assistance with this work.

Severe acute respiratory syndrome coronavirus 2, isolate USA-WA1/2020, NR-52281 was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH. Middle East respiratory syndrome coronavirus, Florida/USA-2_Saudi Arabia_2014, NR-50415 was obtained through BEI Resources, NIAID, NIH. Vero African green monkey kidney cells (ATCC CCL-81), FR-243, were obtained through the International Reagent Resource, Influenza Division, WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza, Centers for Disease Control and Prevention, Atlanta, GA, USA.

This work was supported by USDA-Agricultural Research Service (project no. 6040-32000-066-00-D).

About the Author
Dr. Suarez is the research leader for the Exotic and Emerging Avian Viral Disease Research Unit of the Agricultural Research Service, USDA. His primary research interests are in the understanding and control of avian influenza and Newcastle disease viruses in poultry and other emerging viral diseases that threaten the poultry industry.

References

Address for correspondence: Erica Spackman, US National Poultry Research Center, USDA Agricultural Research Service, 934 Station Rd, Athens, GA 30605, USA; email: erica.spackman@usda.gov

Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020


DOI: https://doi.org/10.3201/eid2612.203833

In March 2020, mild signs and symptoms of coronavirus disease developed in a healthy 33-year-old man in Hong Kong. His first infection did not produce virus neutralizing antibodies. In August, he had asymptomatic reinfection, suggesting that persons without a robust neutralizing antibody response might be at risk for reinfection.
Lack of Susceptibility to SARS-CoV-2 and MERS-CoV in Poultry

Appendix

Detailed Methods

Viruses

The USA-WA1/2020 (BEI NR-58221) (1) isolate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the Florida/USA-2_SaudiArabia_2014 isolate of Middle East respiratory syndrome coronavirus (MERS-CoV) (BEI NR-50415) (2) were both obtained from Biodefense and Emerging Infections Research Resources Repository, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Both viruses were propagated and titrated in CCL-81 Vero cells (International Reagent Resource FR-243). SARS-CoV-2 was utilized at 5 total passages in Vero cells, and MERS-CoV was utilized at 6 total passages in Vero cells. Viruses were used under the approval of the US National Poultry Research Center Institutional Biosafety Committee.

Evaluation of Virus Replication in Avian Species

Five poultry species were selected because of their prevalence worldwide: chickens (Gallus gallus domesticus), turkeys (Meleagris gallopavo), Pekin ducks (Anas platyrhinchos domesticus), Japanese quail (Coturnix japonica), and in wet markets in China: chickens, Pekin ducks, quail, and Chinese domestic geese (Anser cygnoides). Chickens and turkeys were obtained from in-house specific pathogen free (SPF) flocks. Ducks, geese, and quail were obtained from a commercial hatchery. The US National Poultry Research Center Institutional Animal Care and Use Committee reviewed and approved all procedures involving animals.

The experimental design was informed by prior work with testing poultry for the susceptibility and pathogenesis of other novel viruses, avian coronaviruses, or viruses with similar expected pathogenesis (i.e. respiratory tract infection here) in poultry (3-8). We aimed to use a high dose; for most viruses $10^5-10^6$ infectious units is adequate to achieve infection and is
generally not too artificially high for the dose to which an animal would be exposed to in the real world. The simulated respiratory route was utilized, which would mimic a natural route of infection.

Each bird was individually tagged for identification. For each species 10 birds were challenged with each virus and 3 birds were not inoculated to serve as age-matched controls.

Blood was collected from all birds immediately prior to infection and was tested by microneutralization for antibodies to the appropriate challenge virus. Chickens, turkeys, and quail were challenged at 4 weeks of age; ducks and geese were challenged at 2 weeks of age (Appendix Table). Chickens, turkeys, and quail were challenged with $5.4 \log_{10} 50\%$ tissue culture infectious doses ($TCID_{50}$) of SARS-CoV-2 in 0.1mL or $5.2 \log_{10} TCID_{50}$ of MERS-CoV in 0.1mL by the intrachoanal route. Ducks and geese were challenged with $6.0 \log_{10} TCID_{50}$ of SARS-CoV-2 or $5.5 \log_{10} TCID_{50}$ of MERS-CoV, each in 0.1mL by the intrachoanal route. Birds were observed a minimum of daily for clinical signs.

Oropharyngeal (OP) and cloacal (CL) swabs were collected from all challenged birds at 2, 4, and 7 days post challenge (DPC) and were tested for virus by real-time reverse transcription RT-PCR. The rRT-PCR was run with the 2, 4, and 7 DPC samples immediately after the 7 DPC samples were collected. Because they were negative, we determined that it was not necessary to test at any later time points.

Because there was no evidence of infection and no clinical signs, and no virus was excreted by the respiratory tract or intestinal tracts, lesions were not expected to have developed, therefore no birds were necropsied during the course of the study.

At 14 DPC blood was collected from all surviving birds and the serum samples were tested by microneutralization to evaluate whether there was an antibody response to the challenge virus.

**Replication in Embryonating Chicken's Eggs**

Embryonating chicken eggs (ECE) were evaluated for their ability to support replication of SARS-CoV-2 and MERS-CoV. Procedures were identical for both viruses. Five ECE were inoculated with $10^{6.5} TCID_{50}$ in 0.2mL for each of the 3 most common routes of inoculation:
yolk sac (YS), chorioallantoic sac (CAS), and chorioallantoic membrane (CAM). Established inoculation procedures for each route were utilized (9). Eggs were candled daily for viability.

Samples were collected from the inoculated eggs when the embryo was found to be nonviable or at the end of the incubation period. Yolk, allantoic fluid/albumin, embryo tissue (2–3 grams of viscera and thigh muscle) were collected from YS inoculated eggs. Allantoic fluid/albumin, embryo tissues were collected from CAS inoculated eggs, and allantoic fluid/albumin, embryo tissues, and egg membrane were collected from CAM inoculated eggs. During sample collection the embryos were dissected to observe lesions. Age-matched noninoculated ECE served as controls.

CAM and embryo tissues were homogenized in PBS with glass beads in a FastPrep 24 (MP Biomedical LLC, https://www.mpbio.com) then was centrifuged at 17 Kxg for 10 minutes and the supernatant was used for the second passage and for RNA extraction for subsequent testing by rRT-PCR. Allantoic fluid/albumin was used directly for the second passage and RNA extraction. To complete the second passage, all sample material from the 5 eggs of same inoculation route were pooled. The material was then inoculated identically to the first passage. Material from both passages was tested by inoculation into Vero cells in triplicate for fluid and embryo material from each inoculation route as described above to test for the presence of virus.

**Microneutralization**

Virus microneutralization with serum from each species was conducted with both SARS-CoV-2 and MERS-CoV in CCL-81 Vero cells as described by Algaissi and Hashem (10), with the modifications that the dilutions of serum tested were 1:4, 1:8, 1:16, and 1:32 and that the antibody-treated virus was added when the cells were plated. Titers >1:8 were considered positive. Positive control antibodies were commercially available monoclonal antibodies to the S2 region of the spike protein: SARS-CoV-2 used at 12.5μg/mL (MP Biomedical), and MERS-CoV used at 20μg/mL (EastCoast Bio, https://eastcoastbio.com ).

**RNA Extraction and Quantitative Real-Time RT-PCR**

RNA was extracted from OP and CL swab material with the Ambion Magmax kit (ThermoFisher, https://thermofisher.com) as described previously (11). The rRT-PCR primers, probe, and cycling conditions for SARS-CoV-2 for the N1 primer and probe set from the US Centers for Disease Control were utilized (12). The N3 primers, probe, and conditions reported
by Lu et al. which target the nucleoprotein gene was used for MERS-CoV detection (13). The AgPath ID one-step RT-PCR kit was used and the RT step of the reaction conditions was modified to accommodate the recommended kit conditions (PCR conditions recommended for each primer and probe set from the original protocols were used). A standard curve of RNA titrated virus was run in duplicate with each run of rRT-PCR to estimate titer equivalents of virus present in samples.

References


**Appendix Table.** Age at challenge and dose for each virus by species in study of SARS-CoV-2 and MERS-CoV in poultry

<table>
<thead>
<tr>
<th>Species</th>
<th>Age at challenge, wk</th>
<th>Titer of challenge with SARS-CoV-2 (log_{10} TCID_{50}/bird)</th>
<th>Titer of challenge with MERS-CoV (log_{10} TCID_{50}/bird)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chickens (<strong>Gallus gallus domesticus</strong>)</td>
<td>4</td>
<td>5.4</td>
<td>5.2</td>
</tr>
<tr>
<td>Turkeys (<strong>Meleagris gallopavo</strong>)</td>
<td>4</td>
<td>5.4</td>
<td>5.2</td>
</tr>
<tr>
<td>Japanese quail (<strong>Coturnix japonica</strong>)</td>
<td>4</td>
<td>5.4</td>
<td>5.2</td>
</tr>
<tr>
<td>Pekin ducks (<strong>Anas platyrhinchos</strong>)</td>
<td>2</td>
<td>6.0</td>
<td>5.5</td>
</tr>
<tr>
<td>Chinese domestic geese (<strong>Anser cygnoides</strong>)</td>
<td>2</td>
<td>6.0</td>
<td>5.5</td>
</tr>
</tbody>
</table>

*(TCID\textsubscript{50} = 50% tissue culture infectious dose). MERS-CoV Middle East respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.*